NCT01879553View on ClinicalTrials.gov

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Human Influenza
Interventions
BIOLOGICAL

TIV

Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)

Trial Locations (1)

9000

Ghent University & Hospital; CEVAC: Center for Vaccinology,, Ghent

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY

NCT01879553 - Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above | Biotech Hunter | Biotech Hunter